We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
Read MoreHide Full Article
GSK plc (GSK - Free Report) announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch for the drug is planned in second-half 2025 under the brand name Blujepa.
This approval for Blujepa marks the introduction of a new class of oral antibiotics for uUTIs in nearly 30 years. Per GSK, the drug targets a different part of the bacteria than most existing antibiotics, making it effective against resistant strains. Additionally, the risk of bacterial resistance is low, as mutations would need to occur in both enzymes that Blujepa targets.
The drug has been designed to treat uUTIs caused by susceptible microorganisms like Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.
GSK Stock’s Performance
Year to date, shares of GSK have gained 14% compared with the industry’s 6% growth.
Image Source: Zacks Investment Research
More on GSK’s Blujepa
The FDA approval is supported by data from two late-stage studies, EAGLE-2 and EAGLE-3, which showed that Blujepa is at least as effective as nitrofurantoin, a leading standard-of-care (SOC) therapy for uUTIs. In EAGLE-2, the drug met its primary goal of non-inferiority, with a therapeutic success rate of 50.6% versus 47.0% for nitrofurantoin. Data from the EAGLE-3 study showed Blujepa’s superiority, with a success rate of 58.5% compared to 43.6% for nitrofurantoin.
Besides uUTI, GSK is also evaluating the safety and efficacy of Blujepa to ceftriaxone plus azithromycin in patients with uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae.
The drug is one of five new products/line extensions GSK expects this year, potentially boosting its bottom line amid declining vaccine sales. Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type II inflammation), Nucala (for chronic obstructive pulmonary disease) and the pentavalent MenABCWY meningococcal vaccine.
Blujepa has been developed internally by GSK scientists, with part-funding from the U.S. government.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have increased from $6.75 to $7.21 during the same period. Year to date, shares of ANIP have risen 20%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%.
In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to earnings of 25 cents. During the same timeframe, estimates for loss per share for 2026 have narrowed from 65 cents to 31 cents. Year to date, shares of CytomX have lost 40%.
CTMX’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 180.70%.
Estimates for 89bio’s loss per share have narrowed from $3.07 to $1.98 for 2025 in the past 60 days. During the same time frame, loss per share estimates for 2026 have improved from $2.49 to $2.15. ETNB’s shares have gained more than 2% year to date.
89bio’s earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 46.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
GSK plc (GSK - Free Report) announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch for the drug is planned in second-half 2025 under the brand name Blujepa.
This approval for Blujepa marks the introduction of a new class of oral antibiotics for uUTIs in nearly 30 years. Per GSK, the drug targets a different part of the bacteria than most existing antibiotics, making it effective against resistant strains. Additionally, the risk of bacterial resistance is low, as mutations would need to occur in both enzymes that Blujepa targets.
The drug has been designed to treat uUTIs caused by susceptible microorganisms like Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.
GSK Stock’s Performance
Year to date, shares of GSK have gained 14% compared with the industry’s 6% growth.
Image Source: Zacks Investment Research
More on GSK’s Blujepa
The FDA approval is supported by data from two late-stage studies, EAGLE-2 and EAGLE-3, which showed that Blujepa is at least as effective as nitrofurantoin, a leading standard-of-care (SOC) therapy for uUTIs. In EAGLE-2, the drug met its primary goal of non-inferiority, with a therapeutic success rate of 50.6% versus 47.0% for nitrofurantoin. Data from the EAGLE-3 study showed Blujepa’s superiority, with a success rate of 58.5% compared to 43.6% for nitrofurantoin.
Besides uUTI, GSK is also evaluating the safety and efficacy of Blujepa to ceftriaxone plus azithromycin in patients with uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae.
The drug is one of five new products/line extensions GSK expects this year, potentially boosting its bottom line amid declining vaccine sales. Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type II inflammation), Nucala (for chronic obstructive pulmonary disease) and the pentavalent MenABCWY meningococcal vaccine.
Blujepa has been developed internally by GSK scientists, with part-funding from the U.S. government.
GSK’s Zacks Rank
GSK currently carries a Zacks Rank #3 (Hold).
GSK PLC Sponsored ADR Price
GSK PLC Sponsored ADR price | GSK PLC Sponsored ADR Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are ANI Pharmaceuticals (ANIP - Free Report) , CytomX Therapeutics (CTMX - Free Report) and 89bio (ETNB - Free Report) . While ANIP and CTMX sport a Zacks Rank #1 (Strong Buy) each at present, ETNB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have increased from $6.75 to $7.21 during the same period. Year to date, shares of ANIP have risen 20%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%.
In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to earnings of 25 cents. During the same timeframe, estimates for loss per share for 2026 have narrowed from 65 cents to 31 cents. Year to date, shares of CytomX have lost 40%.
CTMX’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 180.70%.
Estimates for 89bio’s loss per share have narrowed from $3.07 to $1.98 for 2025 in the past 60 days. During the same time frame, loss per share estimates for 2026 have improved from $2.49 to $2.15. ETNB’s shares have gained more than 2% year to date.
89bio’s earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 46.18%.